Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

OBJECTIVE: Clinical trial results have shown that, in glucocorticoid‐treated patients, treatment with denosumab 60 mg subcutaneously once every 6 months (Q6M) increased spine and hip bone mineral density (BMD) at month 12 significantly more than treatment with risedronate 5 mg orally once daily (QD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Saag, Kenneth G., Pannacciulli, Nicola, Geusens, Piet, Adachi, Jonathan D., Messina, Osvaldo D., Morales‐Torres, Jorge, Emkey, Ronald, Butler, Peter W., Yin, Xiang, Lems, Willem F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Osteoporosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619388/
https://www.ncbi.nlm.nih.gov/pubmed/30816640
http://dx.doi.org/10.1002/art.40874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619388/
https://www.ncbi.nlm.nih.gov/pubmed/30816640
http://dx.doi.org/10.1002/art.40874

Ejemplares similares